Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierMost of our PH products were initially approved to treat only PAH. In March 2021, Nebulized Tyvaso was approved to treat PH-ILD in addition to PAH. In May 2022, we also obtained FDA approval of Tyvaso DPI to treat both PAH and PH-ILD. We are engaged in further research and development of additional indications for Nebulized Tyvaso to treat certain fibrotic lung conditions underlying PH-ILD. For further details, see Research and Development below.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $781.5MThe company’s own SEC segment disclosure.
- Tyvaso DPI$330.3M42%
- Orenitram$135.6M17%
- Nebulized Tyvaso$127.2M16%
- Remodulin$126.6M16%
- Unituxin$53.6M7%
- Product And Service Other$5.3M1%
- Other (1)$2.9M0%
United Therapeutics Corporation (UTHR) reported revenue of $782M in Q1 2026 (quarter ended March 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $275M (35% of revenue). For the full year FY2025, revenue was $3.18B (+11% year on year) and net income $1.33B. Its largest product in 2026-Q1 was Tyvaso DPI at $330M, 42% of the disclosed total, just ahead of Orenitram at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #6 of 28 by Smart Score